Joke Collection Website - Public benefit messages - What is the stock code of China Medicine?

What is the stock code of China Medicine?

China pharmaceutical stocks cover the whole industrial chain of pharmaceutical R&D production and sales, and have strong industrial strength and core competitive advantages. Thanks to the support of national policies and the growth of market demand, the company's business scale continues to expand and its performance continues to grow steadily. What is the stock code of China Pharmaceutical brought by Bian Xiao? Let's take a look at it together, hoping to bring some reference.

The stock code of China Pharmaceutical is 600056. If you want to know more information, you can download a stock software to check it out. I hope the answer will help you.

Can China pharmaceutical stocks be held for a long time?

Of course. Although compared with foreign countries, the bubble of China's pharmaceutical stocks is very heavy, with the continuous support of policies, pharmaceutical stocks are still a good variety to resist inflation and economic cycles.

China Pharmaceutical Group Co., Ltd. is the only central pharmaceutical enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. Founded in 1998, it is a comprehensive life and health industry group with comprehensive strength and leading scale in China and even Asia.

The enterprise has a large healthy industrial chain integrating scientific and technological research and development, industrial manufacturing, logistics and distribution, retail chain, medical and health care, international operation and financial investment.

On August 2nd, 2002/kloc-0, the Fortune Global 500 list was released in 2002/kloc-0, and China Pharmaceutical Group Co., Ltd. ranked 109.

Sinopharm Group is making every effort to promote the comprehensive construction of its five platforms-modern logistics distribution integrated operation platform, Industry-University-Research integrated scientific and technological innovation platform, international operation integrated platform, medical and health industry platform and efficient management integrated integrated platform. Form five complete coverage networks-national pharmaceutical logistics distribution network, national pharmaceutical retail chain network, national narcotic drug distribution network, national biological product marketing and cold chain distribution network, and national medical device consumables product distribution network. Promote the all-round development of the Group's eleven businesses of modern pharmaceutical logistics and distribution, pharmaceutical retail, biological products, chemical pharmacy, modern Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical research and engineering design, pharmaceutical international operation and overseas industries, pharmaceutical exhibitions and media, and medical and health industries, and form an innovative enterprise with the core competitiveness of medical and health industries.

The distribution network of Pharmaceutical Group covers 365,438+0 provinces, autonomous regions and municipalities directly under the Central Government, and it has 30 distribution centers that meet international standards. It is the largest biological R&D and production enterprise in China, and undertakes more than 80% of the national immunization program vaccine production tasks. The Group has established production bases and medicinal materials bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infective drugs, anti-tumor drugs, cardiovascular and cerebrovascular drugs and respiratory drugs, and has the strongest applied pharmaceutical research institutions and engineering design institutes in China.

Why can't China pharmaceutical stocks be bought?

Because the internet channel can't be purchased. According to the information about China pharmaceutical stocks, we know that China pharmaceutical stocks can't be bought, because Internet channels can't be bought. On February 26th, 2022, China Pharmaceutical Co., Ltd. 65438+ stated that Paciclovir, an oral drug of Pfizer COVID-19 Company, was a prescription drug and needed to be purchased according to the diagnosis of the hospital, but it could not be purchased through Internet channels.

On August 2nd, 2002/kloc-0, the Fortune Global 500 list was released in 2002/kloc-0, and China Pharmaceutical Group Co., Ltd. ranked 109.

Can pharmaceutical stocks still be bought now?

You can buy it. In the long run, the trend of making money in the pharmaceutical industry still exists.

According to relevant data, at present, the per capita medical expenditure in China is only $420, while that in the United States is as high as $9,403 and that in Japan is $3,703. China's population structure and development trend are very similar to those of Japan. In contrast, there is still room for a nine-fold increase in per capita medical expenditure. In the long run, with the arrival of the aging population, the pharmaceutical industry will be a gold mine that investors can't ignore. In the short and medium term, coupled with the outbreak of COVID-19 epidemic in 2020, the worries about profits, performance and capital in the pharmaceutical industry have been accelerated. By the end of 20021and 65438+2, the total market value of A shares was about 80 trillion, and the pharmaceutical industry accounted for about 9%. Ten years ago, this figure was only 3%. With the upgrading of medical consumption and the aging of population, the pharmaceutical industry in COVID-19 has a bright future. There are two reasons:

1. With the aging population, the demand for medical care has exploded. Everyone can certainly feel that the trend of population aging in China is becoming more and more obvious. We can use some data to illustrate this trend: by the end of 20 17, the population over 65 in China was1580,000, accounting for 1 1.39% of the total population, and the growth rate of the population over 65 remained at around 10%. However, the probability of human illness will gradually increase with age. According to the forecast of China Health Statistics Yearbook, the number of chronic diseases among the elderly in China is increasing.

Secondly, the defensive nature of the pharmaceutical industry is deeply loved by institutions. The pharmaceutical industry is a typical weak cyclical industry with high demand rigidity and low elasticity, which is less affected by the macro-economy. Therefore, the pharmaceutical industry has strong defensive characteristics. Even if the macro-economy of the whole country is depressed, the pharmaceutical industry index may rise. Take the Japanese stock market as an example. From 1992 to 20 12, Japan's economy fell into a "lost twenty years". The Nikkei index fell by 25.6%, while the pharmaceutical industry index rose by 92%. The performance of 14 pharmaceutical industry index was better than that of the Nikkei index. On the other hand, A shares have the tradition of "drinking and taking medicine". When the market is bad, institutional funds will hold together liquor stocks and pharmaceutical stocks. Without him, liquor and medicine have performance support. Liquor and medicine have always been the heart of the organization. It's hard to say what kind of diseases China people will get in the future due to smog and gutter oil, but one thing is certain: there will be a great demand for medicines in the future. Strong industry demand and strong market recognition. This is the core reason of the myth of making money in the pharmaceutical industry. Generally speaking, the pharmaceutical industry is a track worthy of our long-term attention.

What are the pharmaceutical stocks in China?

Hengrui Pharma 1

Jiangsu hengrui Pharmaceutical Co., Ltd. was approved by the People's Government of Jiangsu Province, and was jointly established by five promoters including Lianyungang Hengrui Group Co., Ltd. in April. 1997. It is the largest research, development and production base of anti-tumor drugs in China.

2. East China Medicine

Hangzhou Huadong Pharmaceutical Group Company, formerly known as Zhejiang Pharmaceutical Factory, was founded in 1952, and later renamed Hangzhou No.2 Pharmaceutical Factory and Hangzhou Huadong Pharmaceutical Factory.

1992 12 16, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, and has now developed into a joint-stock enterprise-Huadong Pharmaceutical Co., Ltd. and four Sino-foreign joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Moshadong Pharmaceutical Co., Ltd., Hangzhou Jiuyuan Genetic Engineering Co., Ltd. and Zhejiang Huayi Pharmaceutical Co., Ltd.).

3. Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Co., Ltd. was established in 1989, and its predecessor was Linhai Hongqiao Synthetic Chemical Plant. In 200 1 year, it was changed to Zhejiang huahai pharmaceutical co., ltd. In March 2003, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceutical, stock code: 60052 1.

4. Puli Pharmaceutical

Hainan Puli Pharmaceutical Co., Ltd., established in 1992, is a high-tech enterprise specializing in the research, development, production and sales of chemical pharmaceutical preparations, and has passed the certification of leading pharmaceutical enterprises in China. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.

5. Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. was established in 1974, and has now developed into a national key high-tech enterprise and one of the top 100 pharmaceutical enterprises in China. In July 2004, it was successfully listed on Shenzhen Stock Exchange.

6. Xinlitai

Shenzhen Xinlitai Pharmaceutical Co., Ltd. has been approved by the Ministry of Commerce of People's Republic of China (PRC) (Reply of the Ministry of Commerce [2007]No. 10 16), and obtained the Approval Certificate for Overseas Investment Enterprises from People's Republic of China (PRC), Hong Kong, Macao and Taiwan issued by the Ministry of Commerce. On June 29th, 2007, Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Xinlitai") was established as a wholly foreign-owned company with a registered capital of RMB 85 million, and obtained the Business License of Enterprise as a Legal Person with the registration number of 440301501kloc-0/24347.

Previous article:Russia said: 283 1 mercenaries have been eliminated since the conflict between Russia and Ukraine! Where do these mercenaries come from?
Next article:How to cancel Weibo account?